Chromosome 2q12, the ADRA2B I/D polymorphism and metabolic syndrome

Journal of Hypertension

Volumn 27, Issue 9, 2009, Pages 1794-1803

  Fava, Cristiano ^a,b   Montagnana, Martina ^b   Guerriero, Massimo ^c   Almgren, Peter ^a   Von Wowern, Fredrik ^a   Minuz, Pietro ^b   Melander, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Biomedical and Surgical Sciences ^*  (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Adrenergic receptor 2b; Association; Blood pressure; Chromosome 2; Linkage; Metabolic syndrome; Polymorphism; Waist

Indexed keywords

ADRA2B GENE; ADULT; ALLELE; ARTICLE; CHROMOSOME 2Q; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GENE; GENE MAPPING; GENETIC LINKAGE; GENOTYPE; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; PULSE PRESSURE; QUANTITATIVE TRAIT; SWEDEN;

EID: 73249130357     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832d3f9c     Document Type: Article

References (58)

1. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173:309-314. (Pubitemid 38469801)
2. Noto D, Barbagallo CM, Cefalu AB, Falletta A, Sapienza M, Cavera G, et al. The metabolic syndrome predicts cardiovascular events In subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008; 197:147-153. (Pubitemid 351278405)
3. Dekker JM, Glrman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112:666-673. (Pubitemid 41099045)
4. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease In nondiabetic subjects: a populationbased study comparing three different definitions. Diabet Med 2007; 24:464-472. (Pubitemid 46669326)
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285:2486-2497.
6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-480.
7. McQueen MB, Bertram L, Rimm EB, Biacker D, Santangelo SL. A QTL genome scan of the metabolic syndrome and Its component traits. BMC Genet 2003; 4 (Suppl 1):S96.
8. von Wowern F, Bengtsson K, Lindgren CM, Orho-Melander M, Fyhrquist F, Lindblad U, et al. A genome wide scan for early onset primary hypertension in Scandinavians. Hum Mol Genet 2003; 12:2077-2081. (Pubitemid 37038816)
9. Koivukoskl L, Fisher SA,Kanninen T, Lewis CM, von Wowern F, Hunt S, et al. Meta-analysis of genome-wide scans for hypertension and blood pressure in Caucasians shows evidence of susceptibility regions on chromosomes 2 and 3. Hum Mol Genet 2004; 13:2325-2332. (Pubitemid 39359929)
10. Ng MC, So WY, Lam VK, Cockram CS, Bell Gl, Cox NJ, Chan JC. Genomewide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 2004; 33:2676-2683. (Pubitemid 39299278)
11. van Tilburg JHO, Sandkuijl LA, Strengman E, van Someren H, Rigters-Aris CAE, Pearson PL, et al. A genome-wide scan in type 2 diabetes mellitus provides independent replication of a susceptibility locus on 18p11 and suggests the existence of novel Loci on 2q12 and 19q13. J Clin Endocrinol Metab 2003; 88:2223-2230. (Pubitemid 36549900)
12. Li X, Quinones MJ, Wang D, Bulnes-Enriquez I, Jimenez X, De La Rosa R, et al. Genetic effects on obesity assessed by bivariate genome scan: the Mexican-American coronary artery disease study. Obesity (Silver Spring) 2006; 14:1192-1200. (Pubitemid 46219685)
13. Olswold C, de Andrade M. Localization of genes involved in the metabolic syndrome using multivariate linkage analysis. BMC Genet 2003; 31 :S57.
14. Stein CM, Song Y, Elston RC, Jun G, Tiwari HK, Iyengar SK. Structural equation model-based genome scan for the metabolic syndrome. BMC Genef 2003; 31 :S99.
15. Turner ST, Kardia SLR, Boerwinkle E, Andrade Md M. Multivariate linkage analysis of blood pressure and body mass index. Genef Epidemiol 2004; 27:64-73. (Pubitemid 38808346)
16. Regan JW, Kobllka TS, Yang-Feng TL, Caron MG, Lefkowitz RJ, Kobilka BK. Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype. Proc Natl Acad Sci U S A 1988; 85:6301-6305. (Pubitemid 18219156)
17. Heinonen P, Koulu M, Pesonen U, Karvonen MK, Rissanen A, Laakso M, et al. Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 1999; 84:2429-2433. (Pubitemid 30670875)
18. Small KM, Brown KM, Forbes SL, Liggett SB. Polymorphic deletion of three intracellular acidic residues of the a2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 2001 ; 276:4917-4922. (Pubitemid 37371381)
19. Siitonen N, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, llanne-Parikka P, et al. Association between a deletion/insertion polymorphism in the alpha2B-adrenergic receptor gene and insulin secretion and Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologla 2004; 47:1416-1424. (Pubitemid 39232428)
20. Sivenlus K, Lindi V, Niskanen L, Laakso M, Uusitupa M. Effect of a three amino acid deletion in the a2B-adrengergic receptor gene on long-term body weight change in Finnish nondiabetic and type 2 diabetic subjects. Int J Obes Relat Metab Disord 2001; 25:1609-1614. (Pubitemid 33052068)
21. Sivenlus K, Niskanen L, Laakso M, Uusitupa M. A deletion in the a2Badrenergic receptor gene and autonomic nervous function in central obesity. Obes Res 2003; 11:962-970. (Pubitemid 41137508)
22. Snapir A, Heinonen P, Tuomalnen TP, Alhopuro P, Karvonen MK, Lakka TA, et al. An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001 ; 37:1516-1522.
23. Snapir A, Mikkelsson J, Perola M, Penttila A, Schelnin M, Karhunen PJ. Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 2003; 41:190-194. (Pubitemid 36092182)
24. Sykiotis GP, Polyzogopoulou E, Georgopoulos NA, Trakada G, Spyropoulos K, Kalfarentzos F, et al. The alpha2B adrenergic receptor deletion/insertion polymorphism in morbid obesity. Clin Auton Res 2003; 13:203-207. (Pubitemid 36936663)
25. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993; 233:45-51.
26. Fava C, Burri P, Almgren P, Groop L, Hulthén UL, fvlelander O. Heritabllity of ambulatory and office blood pressure phenotypes in Swedish families. J Hypertens 2004; 22:1717-1721. (Pubitemid 39141963)
27. Berglund G, Eriksson KF, lsraelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmo Preventive Project. J Intern Med 1996; 239:489-497.
28. Balkau B, Charles M-A, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28:364-376. (Pubitemid 35434310)
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
30. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998; 63:259-266.
31. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998; 62:1198-1211. (Pubitemid 28199022)
32. Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. Am J Hum Genef 2000; 66:279-292.
33. Atwood LD, Samollow PB, Hixson JE, Stern MP, MacCluer JW. Genomewide linkage analysis of pulse pressure in Mexican Americans. Hypertension 2001 ; 37:425-428. (Pubitemid 32199005)
34. Bielinski SJ, Lynch Al, Miller MB, Weder A, Cooper R, Oberman A, et al. Genome-wide linkage analysis for loci affecting pulse pressure: the Family Blood Pressure Program. Hypertension 2005; 46:1286-1293. (Pubitemid 43189725)
35. Camp NJ, Hopkins PN, Hasstedt SJ, Coon H, Malhotra A, Cawthon RM, Hunt SC. Genome-wide multipoint parametric linkage analysis of pulse pressure in large, extended Utah pedigrees. Hypertension 2003; 42:322-328. (Pubitemid 37093480)
36. DeStefano AL, Larson MG, Mitchell GF, Benjamin EJ, Vasan RS, Li J, et al. Genome-wide scan for pulse pressure in the National Heart, Lung and Blood Institute's Framingham Heart Study. Hypertension 2004; 44:152-155. (Pubitemid 39014231)
37. Turner ST, Fornage M, Jack CRJ, Mosley TH, Kardia SLR, Boerwinkle E, de Andrade M. Genomic susceptibility loci for brain atrophy in hypertensive sibships from the GENOA study. Hypertension 2005; 45:793-798. (Pubitemid 40418383)
38. Turner ST, Kardia SLR, Mosley TH, Rule AD, Boerwinkle E, de Andrade M. Influence of genomic loci on measures of chronic kidney disease in hypertensive sibships. J Am Soc Nephrol 2006; 17:2048-2055. (Pubitemid 44036189)
39. Turner ST, Peyser PA, Kardia SLR, Bielak LF, Sheedy PFr, Boerwinkle E, de Andrade M. Genomic loci with pleiotrope effects on coronary artery calcification. Atherosclerosis 2006; 185:340-346. (Pubitemid 43306747)
40. Zintzaras E, Kitsios G, Kent D, Camp NJ, Atwood L, Hopkins PN, Hunt SC. Genome-wide scans meta-analysis for pulse pressure. Hypertension 2007; 50:557-564. (Pubitemid 47312244)
41. Mitchell GF, DeStefano AL, Larson MG, Benjamin EJ, Chen MH, Vasan RS, et al. Heritabllity and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study. Circulation 2005; 112:194-199.
42. Kanagy NL. Alpha(2)-adrenergic receptor signalling in hypertension. Clin Sci (Lond) 2005; 109:431-437.
43. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking a2-adrenergic receptor subtypes b and c. Science 1996; 273:803-805. (Pubitemid 26271527)
44. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the a2B-adrenergic receptor in the development of salt induced hypertension. Hypertension 1999; 33:14-17. (Pubitemid 29061835)
45. Kintsurashvili E, Gavras I, Johns C, Gavras H. Effects of antisense oligodeoxynucleotide targeting of the a2B-adrenergic receptor messenger RNA in the central nervous system. Hypertension 2001 ; 38:1075-1080. (Pubitemid 34252808)
46. Heinonen P, Jartti L, Jarvisalo MJ, Pesonen U, Kaprio JA, Ronnemaa T, et al. Deletion polymorphism in the alpha2B-adrenergic receptor gene is associated with flow-mediated dilatation of the brachial artery. Clin Sci (Lond) 2002; 103:517-524. (Pubitemid 35305637)
47. Snapir A, Koskenvuo J, Toikka J, Orho-Melander M, Hinkka S, Saraste M, et al. Effects of common polymorphisms in the alpha 1A-, alpha2B-, beta1and beta2-adrenoreceptors on haemodynamic responses to adrenaline. Clin Sci 2003; 104:509-520.
48. Suzuki N, Matsunaga T, Nagasumi K, Yamamura T, Shihara N, Morltani T, et al. Alpha(2B)-adrenergic receptor deletion polymorphism associates with autonomic nervous system activity in young healthy Japanese. J Clin Endocrinol Metab 2003; 88:1184-1187. (Pubitemid 36337775)
49. Ueno LM, Frazzatto EST, Batalha LT, Trombetta IC, do Socorro Brasileiro M, lrigoyen C, et al. Alpha2B-adrenergic receptor deletion polymorphism and cardiac autonomic nervous system responses to exercise in obese women. Int J Obes (Lond) 2006; 30:214-220.
50. Wellcome. Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678.
51. Snapir A, Schelnin M, Groop LC, Orho-Melander M. The insertion/deletion variation in the a2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type-2 diabetes. Cardiovasc Diabetol 2003; 24:.
52. von Wowern F, Bengtsson K, Lindblad U, Rastam L, Melander O. Functional variant in the (alpha)2B adrenoceptor gene, a positional candidate on chromosome 2, associates with hypertension. Hypertension 2004; 43:592-597. (Pubitemid 38282433)
53. Zhang H, Li X, Huang J, Li Y, Thijs L, Wang Z, et al. Cardiovascular and metabolic phenotypes in relation to the ADRA2B insertion/deletion polymorphism in a Chinese population. J Hypertens 2005; 23:2201-2207. (Pubitemid 41666750)
54. Etzel JP, Rana BK, Wen G, Parmer RJ, Schork NJ, O'Connor D, Insel PA. Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. Hypertension 2005; 45:1207-1213. (Pubitemid 40770328)
55. Muszkat M, Sofowora GG, Xie HG, Wood AJ, Stein CM. Alpha2B adrenergic receptor 301 -303 deletion polymorphism and vascular alpha2 adrenergic receptor response. Pharmacogenet Genomics 2005; 15:23-28. (Pubitemid 43205523)
56. Muszkat M, Kurnik D, Solus J, Sofowora GG, Xie H-G, Jiang L, et al. Variation in the alpha2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genomics 2005; 15:407-414. (Pubitemid 40835082)
57. Talke P, Stapelfeldt C, Lobo E, Brown R, Scheinin M, Snapir A. Effect of alpha2B-adrenoceptor polymorphism on peripheral vasoconstriction in healthy volunteers. Anesthesiology 2005; 102:536-542. (Pubitemid 40315142)
58. King D, Etzel JP, Chopra S, Smith J, Cadman PE, Rao F, et al. Human response to alpha2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Ther 2005; 77:388-403. (Pubitemid 40719267)